Cue Biopharma, Inc.
CUENASDAQHealthcare● Active
$29.08
$-0.38(-1.29%)
Market Cap$76420146
P/E Ratio—
52W High$41.42
52W Low$4.98
Cue Biopharma, Inc. (CUE) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CUE · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
-$1.08
Est. -$3.30 · +67.3%
Revenue
$0.01B
Est. $0.00B · +127.4%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 4-Quarter EPS Beat Streak
CUE reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$3.83
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$3.83
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 18, 2026 | -$1.69 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 14, 2026 | -$3.30 | -$1.08 | +67.3% | $0.01B | $0.00B | +127.4% |
| ▲ Q1 FY2026 | Mar 16, 2026 | -$2.70 | $0.30 | +111.1% | $0.02B | $0.00B | +2094.2% |
| ▲ Q4 FY2025 | Nov 12, 2025 | -$0.10 | -$0.07 | +30.0% | $0.00B | $0.00B | -6.1% |
| ▲ Q3 FY2025 | Aug 12, 2025 | -$0.13 | -$0.09 | +30.8% | $0.00B | $0.00B | +47.7% |
| ▼ Q2 FY2025 | May 12, 2025 | -$0.14 | -$0.17 | -21.4% | $0.00B | $0.00B | -66.8% |
| ▲ Q1 FY2025 | Mar 31, 2025 | -$0.16 | -$0.13 | +18.8% | $0.00B | $0.00B | -7.4% |
| ▲ Q4 FY2024 | Nov 14, 2024 | -$0.20 | -$0.17 | +15.0% | $0.00B | $0.00B | +119.5% |
Q3 FY2026
Aug 18, 2026
EPS Actual
—
EPS Est.
-$1.69
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026Beat
EPS Actual
-$1.08
EPS Est.
-$3.30
EPS Surpr.
+67.3%
Revenue
$0.01B
Q1 FY2026
Mar 16, 2026Beat
EPS Actual
$0.30
EPS Est.
-$2.70
EPS Surpr.
+111.1%
Revenue
$0.02B
Q4 FY2025
Nov 12, 2025Beat
EPS Actual
-$0.07
EPS Est.
-$0.10
EPS Surpr.
+30.0%
Revenue
$0.00B
Q3 FY2025
Aug 12, 2025Beat
EPS Actual
-$0.09
EPS Est.
-$0.13
EPS Surpr.
+30.8%
Revenue
$0.00B
Q2 FY2025
May 12, 2025Miss
EPS Actual
-$0.17
EPS Est.
-$0.14
EPS Surpr.
-21.4%
Revenue
$0.00B
Q1 FY2025
Mar 31, 2025Beat
EPS Actual
-$0.13
EPS Est.
-$0.16
EPS Surpr.
+18.8%
Revenue
$0.00B
Q4 FY2024
Nov 14, 2024Beat
EPS Actual
-$0.17
EPS Est.
-$0.20
EPS Surpr.
+15.0%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-1.97 | $-1.97 | $-1.97 | 1 |
| Q3 FY2026 | $-1.91 | $-1.91 | $-1.91 | 1 |
| Q2 FY2026 | $-1.69 | $-1.69 | $-1.69 | 1 |
| Q1 FY2026 | $-3.30 | $-3.30 | $-3.30 | 1 |
| Q4 FY2025 | $-2.70 | $-2.70 | $-2.70 | 1 |
| Q3 FY2025 | $-2.80 | $-2.80 | $-2.80 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 14, 2026 | +67.3% | $29.47 | $25.33 | -14.05% |
| ▲ Q1 FY2026 | Mar 16, 2026 | +111.1% | $8.51 | $9.35 | +9.87% |
| ▲ Q4 FY2025 | Nov 12, 2025 | +30.0% | $20.49 | $20.03 | -2.24% |
| ▲ Q3 FY2025 | Aug 12, 2025 | +30.8% | $24.94 | $23.70 | -4.97% |
| ▼ Q2 FY2025 | May 12, 2025 | -21.4% | $23.39 | $22.53 | -3.68% |
| ▲ Q1 FY2025 | Mar 31, 2025 | +18.8% | $27.60 | $27.33 | -0.98% |
| ▲ Q4 FY2024 | Nov 14, 2024 | +15.0% | $45.00 | $45.00 | +0.00% |
| ▲ Q3 FY2024 | Aug 19, 2024 | +31.0% | $20.37 | $22.80 | +11.93% |
Q2 FY2026-14.05%
Report Date
May 14, 2026
EPS Beat/Miss
+67.3%
Price Before
$29.47
Price After
$25.33
Q1 FY2026+9.87%
Report Date
Mar 16, 2026
EPS Beat/Miss
+111.1%
Price Before
$8.51
Price After
$9.35
Q4 FY2025-2.24%
Report Date
Nov 12, 2025
EPS Beat/Miss
+30.0%
Price Before
$20.49
Price After
$20.03
Q3 FY2025-4.97%
Report Date
Aug 12, 2025
EPS Beat/Miss
+30.8%
Price Before
$24.94
Price After
$23.70
Q2 FY2025-3.68%
Report Date
May 12, 2025
EPS Beat/Miss
-21.4%
Price Before
$23.39
Price After
$22.53
Q1 FY2025-0.98%
Report Date
Mar 31, 2025
EPS Beat/Miss
+18.8%
Price Before
$27.60
Price After
$27.33
Q4 FY2024+0.00%
Report Date
Nov 14, 2024
EPS Beat/Miss
+15.0%
Price Before
$45.00
Price After
$45.00
Q3 FY2024+11.93%
Report Date
Aug 19, 2024
EPS Beat/Miss
+31.0%
Price Before
$20.37
Price After
$22.80
Avg Beat Reaction-0.06%
Avg Miss Reaction-3.68%
Beat Rate7 / 8 quarters
Largest Move-14.05% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CUE ends December
Cue Biopharma, Inc. (CUE) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $-1.08 — beating the analyst consensus of $-3.30 by +67.3%. CUE has beaten EPS estimates for 4 consecutive quarters. The next CUE earnings date is expected around September 1, 2026.
Each quarter, investors track CUE earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CUE revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CUE's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CUE earnings · 5 questionsCue Biopharma, Inc.'s next earnings report is expected around September 1, 2026. CUE typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CUE historically reports after market close (AMC).
CUE earnings datewhen is CUE earningsCUE next earnings datewhen does CUE report earningsCUE earnings calendar
▸ Source: FMP · Cue Biopharma, Inc. SEC filings · US GAAP · Cue Biopharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026